We hypothesize that GEM treatment stimulates G9a expression in pancreatic cancer cells that in turn enriches a population of G9a-overexpressing stem-like cancer cells to produce IL-8 to modulate tumor microenvironment to increase GEM resistance. Here, EHMT2 is linked to pancreatic neoplasm.